Medindia LOGIN REGISTER
Medindia
Advertisement

Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008

Friday, May 23, 2008 General News
Advertisement
SAN DIEGO, May 23 Cardium Therapeutics(Amex: CXM) today announced that its annual meeting of stockholders will beheld on June 5, 2008 at 9:00 a.m. Pacific Time, at the San Diego Marriott DelMar, 11966 El Camino Real, San Diego, California. The record date forstockholders entitled to vote at the annual meeting is April 10, 2008.
Advertisement

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc.and the Tissue Repair Company, are medical technology companies primarilyfocused on the development, manufacture and sale of innovative therapeuticproducts and devices for cardiovascular, ischemic and related indications.Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec,Ad5FGF4), is a DNA-based growth factor therapeutic being developed forpotential use by interventional cardiologists as a one-time treatment topromote and stimulate the growth of collateral circulation in the hearts ofpatients with ischemic conditions such as recurrent angina. For moreinformation about Cardium and its businesses, products and therapeuticcandidates, please visit http://www.cardiumthx.com or view its 2007 AnnualReport at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.
Advertisement

Cardium's InnerCool Therapies subsidiary is a San Diego-based medicaltechnology company in the emerging field of patient temperature modulationtherapy to rapidly and controllably cool the body in order to reduce celldeath and damage following acute ischemic events such as cardiac arrest orstroke, and to potentially lessen or prevent associated injuries such asadverse neurological outcomes. For more information about Cardium's InnerCoolsubsidiary, including InnerCool's RapidBlue(TM) and CoolBlue(TM) patientmodulation systems, please visit http://www.innercool.com.

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-basedbiopharmaceutical company focused on the development of growth factortherapeutics for the treatment of severe chronic diabetic wounds. TRC's leadproduct candidate, Excellarate(TM), is a DNA-activated collagen gel fortopical treatment formulated with an adenovector delivery carrier encodinghuman platelet-derived growth factor-BB (PDGF-BB). Excellarate is initiallybeing developed to be administered once or twice for the potential treatmentof non-healing diabetic foot ulcers. Other potential applications for TRC'sGene Activated Matrix(TM) (GAM(TM)) technology include therapeuticangiogenesis (cardiovascular ischemia, peripheral arterial disease) andorthopedic products, including hard tissue (bone) and soft tissue (ligament,tendon, cartilage) repair. For more information about Cardium's Tissue RepairCompany subsidiary, please visit http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in thispress release are forward looking and reflect numerous assumptions and involvea variety of risks and uncertainties, many of which are beyond our control andmay cause actual results to differ materially from stated expectations.Actual results may also differ substantially from those described in orcontemplated by this press release due to risks and uncertainties that existin our operations and business environment, including, without limitation,risks and uncertainties that are inherent in the development, testing andmarketing of complex biologics and therapeutic hypothermia devices and in theconduct of human clinical trials, including the timing and costs of suchtrials, our ability to obtain necessary funding, regulatory approvals andqualifications, our dependence upon proprietary technology, our history ofoperating losses and accumulated deficits, our reliance on collaborativerelationships and critical personnel, and current and future competition, aswell as other risks described fr
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close